By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mercury Therapeutics, Inc. 

2E Gill Street

Woburn  Massachusetts  01801  U.S.A.
Phone: 781-932-1125 Fax: 781-935-8140


Company News
AMPK Activator Licensing Deal Highlights Successful Collaboration Between Boston-based Mercury Therapeutics, Inc. and CreaGen Biosciences 10/27/2009 9:29:12 AM
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930 A First-in-Class, Small Molecule Activator of AMPK for Treatment of Type 2 Diabetes 8/4/2009 9:31:43 AM
Mercury Therapeutics, Inc. Outlicenses Research Products Applications of AMP-Activated Protein Kinase to Millipore Corporation (MIL) 5/19/2009 11:19:39 AM
Mercury Therapeutics, Inc. Patents Filed Patents Filed on Lead Compounds That Directly and Specifically Activate AMPK 3/31/2008 10:59:38 AM
Mercury Therapeutics, Inc. Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences, Inc. 3/12/2008 10:49:13 AM
Mercury Therapeutics, Inc. Breakthrough for Patients With Type-2 Diabetes 11/26/2007 8:37:59 AM